Trial · NCT00697515
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Permanent Product Measure of Performance (PERMP) Total Score Over the Treatment Day in the Crossover Phase | 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7 | The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test. The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session. The scores range from 0-800 with higher scores indicating better performance. |
| Secondary | PERMP Total Score by Timepoint in the Crossover Phase | 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7 | The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test. The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session. The scores range from 0-800 with higher scores indicating better performance. |
| Secondary | PERMP Score for the Number of Math Problems Attempted by Timepoint in the Crossover Phase | 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7 | The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test. The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session. The scores range from 0-800 with higher scores indicating better performance. |
| Secondary | PERMP Score for the Number of Math Problems Answered Correctly by Timepoint in the Crossover Phase | 2, 4, 8, 10, 12 and 14 hours post-dose on Day 7 | The Permanent Product Measure of Performance (PERMP) is a skill adjusted math test. The PERMP score is the sum of the number of math problems attempted plus the number of math problems answered correctly in a 10-minute session. The scores range from 0-800 with higher scores indicating better performance. |
| Secondary | Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale With Prompts (ADHD-RS) Total Score at up to 28 Days in the Dose Optimization Phase | Baseline and 7, 14, 21 and 28 days | The Attention Deficit Hyperactivity Disorder Rating Scale with Prompts (ADHD-RS) consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. |
| Secondary | ADHD-RS With Prompts Total Score in the Crossover Phase | 7 days | The Attention Deficit Hyperactivity Disorder Rating Scale with Prompts (ADHD-RS) consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. |
| Secondary | Assessment of Clinical Global Impression-Severity of Illness (CGI-S) in the Dose Optimization Phase | Baseline | CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) |
| Secondary | Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in the Dose Optimization Phase | 7, 14, 21 and 28 days | CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. |
| Secondary | Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in the Crossover Phase | 7 days | CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. |
| Secondary | Change From Baseline in the Brown Attention Deficit Disorder Scale (BADDS) Total Scores at 26 Days in the Dose Optimization Phase | Baseline and 26 days | The BADDS assessment consists of 40 items rated on a scale from 0 (never) to 3 (almost daily). The total score ranges from 0 to 120 with increasing scores indicating more severe impairment. |
| Secondary | Level of Satisfaction With Study Treatment on Medication Satisfaction Questionnaire (MSQ) in the Dose Optimization Phase | 26 days | MSQ is a survey rating the subject's level of satisfaction with the study treatment medication. |
| Secondary | Change From Baseline in Adult ADHD Impact Module (AIM-A) Question 1 Score at 26 Days in the Dose Optimization Phase | Baseline and 26 days | AIM-A is a quality of life instrument. Question 1 is 'On a scale of 1 to 10, how would you rate the overall quality of life right now?' It is rated on a scale of 1 (worst) to 10 (best). |
| Secondary | Change From Baseline in AIM-A Question 4 Score at 26 Days in the Dose Optimization Phase | Baseline and 26 days | AIM-A is a quality of life instrument. Question 4 is 'How much do you agree with this statement: Over the past few weeks, I've had more good days than bad days?' This is rated on a scale of 1 (strongly agree) to 5 (strongly disagree). |
| Secondary | Change From Baseline in Systolic Blood Pressure at Up to 28 Days in the Dose Optimization Phase | Baseline and 7, 14, 21 and 28 days | |
| Secondary | Change From Baseline in Diastolic Blood Pressure at Up to 28 Days in the Dose Optimization Phase | Baseline and 7, 14, 21 and 28 days | |
| Secondary | Change From Baseline in Pulse Rate at Up to 28 Days in the Dose Optimization Phase | Baseline and 7, 14, 21 and 28 days | |
| Secondary | Change From Baseline in Electrocardiogram Results (QTcF Interval) at 7 Days in the Crossover Phase | Baseline and 7 days | QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00697515/registered